Cook Biotech acquires assets of AcuityBio, expanding its technology portfolio
Cook Biotech President Umesh Patel, PhD, said, “This acquisition was the next logical step in our relationship. Our team is very motivated to complete the work to get this combination product in clinicians’ hands to help lung cancer patients.”
Dr. Patel also said, “For more than 25 years, our extracellular matrix (ECM) technology has been used to improve the lives of patients worldwide. Now with AcuityBio’s drug-delivery platform on board, we hope to develop other combination products to locally deliver a diverse set of therapeutic compounds providing solutions for critical unmet medical needs and potentially saving patient lives.”
The terms of the agreement remain confidential.
About Cook Biotech
Cook Biotech Inc. develops and manufactures medical products for tissue repair and regenerative medicine applications using proprietary extracellular matrix (ECM) technologies and processes. Cook Biotech products are marketed and distributed under several brand names, including Biodesign® and OASIS®. Cook Biotech collaborates with partners and distributors, including AxoGen Inc., Aziyo Biologics, Cook Medical Inc., Cormatrix, Katena Products Inc., Keystone Dental Inc., and Smith & Nephew Inc., to develop new products and provide technical support. Cook Biotech was established in 1995 and is affiliated with Cook Medical Holdings in Bloomington, Indiana. It is located in the Purdue Research Park in West Lafayette, Indiana. For more information, visit www.cookbiotech.com.